

# Vertigo, Tinnitus, and Meniere’s Diagnosis Treatment Devices

## Table of Content

- [Purpose](#)
- [Description & Definitions](#)
- [Criteria](#)
- [Coding](#)
- [Document History](#)
- [References](#)
- [Special Notes](#)
- [Keywords](#)

<u>Effective Date</u>	10/2007
<u>Next Review Date</u>	02/2024
<u>Coverage Policy</u>	DME 225
<u>Version</u>	7

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member’s condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.\*

### Purpose:

This policy addresses Vertigo, Tinnitus, and Meniere’s Diagnosis Treatment Devices.

### Description & Definitions:

Acoustic Assistive Devices are devices that are used to treat/manage vertigo, tinnitus and Meniere’s diagnosis.

The dizzyFix device trains individuals to perform the Epley maneuver, repositioning procedure used to treat BPPV (Benign Paroxysmal Positional Vertigo)

The Neuromonics Tinnitus Device is a device that emits music and other tones which filter tinnitus.

The Meniett device delivers low-pressure pulses to the middle ear causing displacement of inner ear fluids.

### Criteria:

Vertigo, Tinnitus, and Meniere’s Diagnosis Treatment Devices **do not meet the definition of medical necessity**, to include but not limited to:

- DizzyFix device
- Meniett device
- Neuromonics Tinnitus Device

### Coding:

Medically necessary with criteria:

Coding	Description
	None

Considered Not Medically Necessary:

Coding	Description
E1399	Durable medical equipment, miscellaneous
E2120	Pulse generator system for tympanic treatment of inner ear endolymphatic fluid

**Document History:**

Revised Dates:

- 2021: February
- 2020: February, March
- 2019: October
- 2013: July
- 2012: July
- 2011: October

Reviewed Dates:

- 2024: February
- 2023: February
- 2022: February
- 2017: December
- 2016: July
- 2015: July
- 2014: July
- 2011: July
- 2010: July
- 2009: July
- 2008: July

Effective Date:

- October 2007

**References:**

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

Code of Federal Regulations. Ecf.gov. Title 21, Chapter 1, Subchapter H, Part 874. 1.22.2024. Retrieved 1.30.2024. <https://www.ecfr.gov/current/title-21/chapter-1/subchapter-H/part-874>

Food and Drug Administration. Office of Device Evaluation (ODE). Division of Ophthalmic and Ear, Nose and Throat Devices (DOED). 2024. Retrieved 1.30.2024. <https://www.fda.gov/media/85334/download>

Hayes. A symplr Company. Emerging Technology Report. Lenire Device (Neuromod Devices Ltd.) for Tinnitus. 3.31.2023. Retrieved 1.30.2024. <https://evidence.hayesinc.com/report/pg.lenire>

Hayes. A symplr Company. Health Technology Assessment. Neuromonics Tinnitus Treatment (Neuromonics Inc.). 10.24.2011. Retrieved 1.30.2024. <https://evidence.hayesinc.com/report/htb.neuromonics1621>

Centers for Medicare and Medicaid Services. CMS.gov. Tinnitus Masking. 50.6. Retired 12.18.2014. Retrieved 1.30.2024. <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=85&ncdver=1&bc=AAAAEAAAAQAA&#:~:text=Tinnitus%20masking%20is%20considered%20an,Therefore%2C%20it%20is%20not%20covered.>

MCG Informed Care Strategies. 27<sup>th</sup> Edition. Positive Pressure Therapy for Meniere Disease. ACG: A-0978 (AC). 2023. Retrieved 1.30.2024. <https://careweb.careguidelines.com/ed27/index.html>

Commonwealth of Virginia. Department of Medical Assistance Services. Provider Manual, Durable Medical Equipment. Chapter IV, Covered Services and Limitations. 1.4.2024. Retrieved 1.30.2024. [https://vamedicaid.dmas.virginia.gov/sites/default/files/2024-01/DME%20Chapter%20IV%20%28updated%201.4.24%29\\_Final.pdf](https://vamedicaid.dmas.virginia.gov/sites/default/files/2024-01/DME%20Chapter%20IV%20%28updated%201.4.24%29_Final.pdf)

National Comprehensive Cancer Network. Guidelines. 2024. Retrieved 1.31.2024. <https://www.nccn.org/search-result?indexCatalogue=nccn-search-index&searchQuery=-%09Acoustic%20Assistive%20Device>

Carelon. Clinical Guidelines and Pathways. 2024. Retrieved 1.31.2024. [https://guidelines.carelonmedicalbenefitsmanagement.com/?s=tinnitus&et\\_pb\\_searchform\\_submit=et\\_search\\_process&et\\_pb\\_include\\_posts=yes&et\\_pb\\_include\\_pages=yes](https://guidelines.carelonmedicalbenefitsmanagement.com/?s=tinnitus&et_pb_searchform_submit=et_search_process&et_pb_include_posts=yes&et_pb_include_pages=yes)

David E. Tunkel, Carol A. Bauer, Gordon H. Sun, Richard M. Rosenfeld, Sujana S. Chandrasekhar, Eugene R. Cunningham, Jr, Sanford M. Archer, Brian W. Blakley, John M. Carter, Evelyn C. Granieri, James A. Henry, Deena Hollingsworth, Fawad A. Khan, Scott Mitchell, Ashkan Monfared, Craig W. Newman, Folashade S. Omole, C. Douglas Phillips, Shannon K. Robinson, Malcolm B. Taw, Richard S. Tyler, Richard Waguespack, and Elizabeth J. Whamond Otolaryngology–Head and Neck Surgery 2014, Tinnitus, 151:4, 533-541. Retrieved 1.31.2024. <https://journals.sagepub.com/doi/epub/10.1177/0194599814547475>

Gregory J. Basura MD, PhD, Meredith E. Adams MD, Ashkan Monfared MD, Seth R. Schwartz MD, MPH, Patrick J. Antonelli MD, Robert Burkard PhD, CCC-A, Matthew L. Bush MD, PhD, Julie Bykowski MD, Maria Colandrea DNP, NP-C, Jennifer Derebery MD, Elizabeth A. Kelly MD, Kevin A. Kerber MD, Charles F. Koopman MD, MHSA, Amy Angie Kuch, Evie Marcolini MD, FCCM, Brian J. McKinnon MD, MBA, MPH, Michael J. Ruckenstein MD, MSC, Carla V. Valenzuela MD, Alexis Vosooney MD, Sandra A. Walsh, Lorraine C. Nnacheta MPH, DrPH, Nui Dhepyasuwan MEd, Erin M. Buchanan MPH. Otolaryngology – Head and Neck Surgery. Clinical Practice Guideline: Ménière's Disease Executive Summary. 4.8.2020. Retrieved 1.31.2024. <https://www.entnet.org/quality-practice/quality-products/clinical-practice-guidelines/menieres-disease/#clinical-practice-guideline-mnires-disease>

Webster, K. E., George, B., Galbraith, K., Harrington-Benton, N. A., Judd, O., Kaski, D., Maarsingh, O. R., MacKeith, S., Ray, J., Van Vugt, V. A., & Burton, M. J. (2023). Positive pressure therapy for Ménière's disease. The Cochrane database of systematic reviews, 2(2), CD015248. Retrieved 1.31.2024. <https://doi.org/10.1002/14651858.CD015248.pub2>

### Special Notes: \*

This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to "correct or ameliorate" (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to by

medically necessary to correct or ameliorate the member's condition. *Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*

All medically necessary medical equipment and supplies under the Virginia Administrative Code (12VAC30-50-165) may be covered only if they are necessary to carry out a treatment prescribed by a practitioner. Only supplies, equipment, and appliances that are determined medically necessary may be covered for reimbursement by DMAS. (12VAC30-50-165) The following criteria must be satisfied through the submission of adequate and verifiable documentation satisfactory to DMAS, or its contractor. Medically necessary DME and supplies shall be:

- Ordered by the practitioner on the CMN/DMAS-352;
- A reasonable and medically necessary part of the individual's treatment plan;
- Consistent with the individual's diagnosis and medical condition, particularly the functional limitations and symptoms exhibited by the individual; • Not furnished for the safety or restraint of the individual, or solely for the convenience of the family, attending practitioner, or other practitioner or supplier;
- Consistent with generally accepted professional medical standards (i.e., not experimental or investigational);
- Furnished at a safe, effective, and cost-effective level; and
- Suitable for use, and consistent with 42 CFR 440.70(b)(3), that treats a diagnosed condition or assists the individual with functional limitations.

#### Keywords:

SHP Acoustic Assistive Devices, Durable Medical Equipment 225, Meniett Device, Meniere's Disease, Neuromonics Tinnitus Device, DizzyFix, Auditory impedance tester, tympanometer, Positive Pressure Therapy (PPT)